Ainos, Inc. (AIMD)
$
1.38
-0.06 (-4.35%)
Key metrics
Financial statements
Free cash flow per share
-1.0234
Market cap
6.7 Million
Price to sales ratio
58.8620
Debt to equity
1.0951
Current ratio
2.9602
Income quality
0.3092
Average inventory
163.5 Thousand
ROE
-1.1935
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ainos, Inc. is a healthcare company that specializes in the development of medical technologies aimed at point-of-care testing and innovative treatments for various disease indications. The company has made significant strides in its financial performance, as evidenced by its operating income ratio of -667.72 indicating the company's operational profitability margin. Additionally, the gross profit ratio stands at -1.54 reflecting the efficiency of the company's production and sales operations. Ainos achieved a revenue of $20,729.00 showcasing its focus on niche markets. However, the company also incurred an interest expense of $616,467.00 highlighting its obligations related to debt servicing. The weighted average number of shares outstanding is 9,503,618.00 which underscores the company's shareholder base and their stake in the firm. Ainos offers a range of products, including a COVID-19 antigen rapid test kit, a cloud-based test management platform, and a low-dose oral interferon alpha formulation known as Very Low-Dose Oral Interferon Alpha, among other technologies. Formerly known as Amarillo Biosciences, Inc., the company rebranded to Ainos, Inc. in May 2021 and has its headquarters in San Diego, California. The company's stock presents an attractive option for budget-conscious investors, as it is affordable at $3.76. However, it's important to note that the stock has a low average trading volume of 670,974.00 indicating lower market activity, which may affect liquidity. With a market capitalization of $6,653,587.00 Ainos is classified as a small-cap player within the healthcare market. It operates within the Biotechnology industry and plays a crucial role in enhancing the overall market landscape. Furthermore, Ainos belongs to the Healthcare sector, where it continues to drive innovation and growth through its advanced medical technologies. The company's strategic focus on point-of-care testing and treatment positions it effectively in the evolving healthcare landscape, allowing it to contribute meaningfully to patient care and medical advancements.
Is Ainos, Inc. (AIMD) a good investment?
Investing in Ainos, Inc. (AIMD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Ainos, Inc. (AIMD)'s stock forecast?
Analysts predict Ainos, Inc. stock to fluctuate between $1.26 (low) and $4.50 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ainos, Inc.'s market capitalization?
As of 2026-03-27, Ainos, Inc.'s market cap is $6,653,587, based on 4,821,440 outstanding shares.
How does Ainos, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Ainos, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ainos, Inc. (AIMD) stock?
To buy Ainos, Inc. (AIMD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AIMD. Place an order (Market, Limit, etc.).
What is the best time to invest in Ainos, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Ainos, Inc. stock ever split?
Ainos, Inc.'s last stock split was 1:5 on 2025-06-30.
How did Ainos, Inc. perform in the last earnings report?
Revenue: $20,729 | EPS: -$1.56 | Growth: -53.57%.
Where can I find Ainos, Inc.'s investor relations reports?
Visit https://ainos.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ainos, Inc.?
You can explore historical data from here
What is the all-time high and low for Ainos, Inc. stock?
All-time high: $90 (2022-08-04) | All-time low: $0.40 (2024-11-15).
What are the key trends affecting Ainos, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
AI Nose deployment into front-end wafer fabrication facilities marks a critical validation step in semiconductor manufacturing environments Recurring revenue visibility strengthens as AI Nose deployments scale across the semiconductor ecosystem HOUSTON, TX / ACCESS Newswire / March 12, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced that Water Tower Research ("WTR") has published a report highlighting Ainos' accelerating momentum across the semiconductor value chain as its AI Nose platform gains traction in both front-end wafer fabrication and back-end semiconductor manufacturing environments. Key Highlights from the Report: Front-end wafer fab entry unlocks a new frontier for AI Nose validation: Ainos plans to deploy approximately 200 AI Nose systems into front-end wafer fabrication facilities in 1Q26.
accessnewswire.com
Company affirms execution milestones, subscription activation roadmap, and long-term infrastructure vision remain unchanged despite market volatility HOUSTON, TEXAS / ACCESS Newswire / March 9, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced continued validation testing of its AI Nose platform within advanced semiconductor front-end wafer fabrication environments. As part of this qualification phase, Ainos plans to install approximately 200 AI Nose systems across targeted front-end facilities in the first quarter of 2026 for technical validation.
accessnewswire.com
HOUSTON, TEXAS / ACCESS Newswire / March 2, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today issued the following letter from Chairman, President and Chief Executive Officer Eddy Tsai to shareholders, outlining the recurring revenue opportunity under the phased deployment framework of up to 20,000 AI Nose systems, and ongoing validation within advanced front-end semiconductor fabrication environments. To Our Shareholders, I'm proud to share that the AI Nose platform is transitioning from validation-stage pilots into structured industrial deployment.
accessnewswire.com
HOUSTON, TEXAS / ACCESS Newswire / February 23, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced the activation of a phased industrial deployment roadmap under a strategic framework that contemplates the installation of up to 20,000 AI Nose units within semiconductor manufacturing environments. Phased Expansion Framework within Back-end Semiconductor Environments The framework under a Memorandum of Understanding with ASE Technology Holding Co., Ltd.
accessnewswire.com
AI Nose commercial deployment accelerates in 2026 with dual-engine architecture, industrial expansion, and recurring SaaS revenue model New Trusval agreement commits to minimum 600-unit deployment, positioning AI Nose into front-end semiconductor manufacturing HOUSTON, TEXAS / ACCESS Newswire / January 12, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced that Water Tower Research ("WTR") has published a report spotlighting the Company's accelerated evolution from SmellTech R&D to large-scale commercial deployment, supported by a scalable AI infrastructure strategy and expanding semiconductor partnerships. Key Highlights from the Report: Scaled commercialization gains momentum in 2026: Ainos enters 2026 with growing momentum as AI Nose advances from a hardware sensing solution into a foundational AI platform that converts scent into structured, machine-readable data for global industrial markets.
accessnewswire.com
Partnership Supports Ainos' 2026 Strategic Focus on Advancing AI Nose Upstream and Accelerating Scent Data Accumulation in Advanced Wafer Fabs HOUSTON, TX / ACCESS Newswire / January 7, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced that it has entered into a distribution and deployment agreement with Trusval Technology, a Taiwan-based engineering and technical services provider specializing in semiconductor manufacturing environments. Pursuant to the agreement, Ainos and Trusval will establish a distribution and deployment partnership within the defined scope of semiconductor front-end manufacturing applications.
accessnewswire.com
A Dual-Engine SmellTech Architecture: Ainos at the Edge, ScentAI Scaling AI Intelligence HOUSTON, TX / ACCESS Newswire / January 2, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) today released a statement from Chairman, President and Chief Executive Officer Eddy Tsai, outlining the Company's long-term platform strategy to digitize smell as a native data language for artificial intelligence, its execution priorities for 2026, and the complementary roles of Ainos and its wholly owned AI software subsidiary, ScentAI Inc. ("ScentAI"), within the SmellTech platform - AI Nose. Ainos is executing a disciplined, long-term strategy to transform smell from a sensory signal into a structured data language that artificial intelligence systems can understand, learn from, and scale.
accessnewswire.com
Relocation to sharpen operating efficiency and anchor Ainos in Texas' fast-growing technology ecosystem New subsidiary to accelerate smell language model development and extend AI Nose's data-driven platform strategy SAN DIEGO, CA / ACCESS Newswire / December 16, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) today announced that it will relocate its U.S. headquarters to Houston, Texas in early 2026 and has formed its wholly owned subsidiary, ScentAI Inc. ("ScentAI"), a pure AI software company created to advance development of its smell language model (SLM)-an emerging AI model that enables scent intelligence for machines by digitizing scent signals into Smell IDs. Ainos will relocate to Houston to strengthen operating efficiency and position its U.S. operations within one of the country's most dynamic technology and industrial innovation hubs.
defenseworld.net
Ainos, Inc. (NASDAQ: AIMD - Get Free Report) traded up 0.5% during trading on Friday. The company traded as high as $1.99 and last traded at $1.92. 20,799 shares changed hands during trading, a decline of 97% from the average session volume of 718,317 shares. The stock had previously closed at $1.91. Wall Street Analyst
accessnewswire.com
Collaboration brings AI Nose to the edge, advancing intelligent sensing and industrial sustainability Partnership taps ~$60 billion edge AI market, expanding global industrial channels and accelerating AI Nose commercialization SAN DIEGO, CALIFORNIA / ACCESS Newswire / October 20, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report highlighting Ainos' strategic partnership with NEXCOM International Co., Ltd. ("NEXCOM"), a Taiwan-based pioneer in industrial computing and edge AI solutions.
See all news
